Accenture and Roche Collaborate to Enhance Digital Healthcare for Cancer Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Accenture plc (ACN) PT Raised to $180 at Cantor Fitzgerald Following Strong 1Q
December 22, 2017 8:03 AM ESTCantor Fitzgerald raised its price target on Accenture plc (NYSE: ACN) to $180.00 (from $151.00) while maintaining a Overweight rating following the company's 1Q. Accenture reported 1QFY18 net revenue of $9.52 bn, vs. guidance of $9.1-9.35 bn and the FactSet consensus of $9.26 bn. Adjusted EPS for 1QFY18 were... More
